TrialBritish journal of clinical pharmacology2025

Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY.

Mita Kuchimanchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.